Please upgrade your browser.
Studies presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrate the flexibility of targeted therapy techniques, where new drugs can be developed and tested in human trials more quickly and safely than ever before. Among the studies presented include a pair of reports on two separate novel insulin-like growth factor receptor enzyme inhibitors, both currently involved in solid tumor clinical trials. In addition, researchers will be offering details on two Phase II trials involving already-approved drugs in new applications: sunitinib in a form of liver cancer and sorafenib, combined with the cell-signaling molecule IL-21, in metastatic renal cancer. Source: HuliQ.com
ZymoGenetics, Inc. today presented positive Phase 1 interim data from a Phase 1/2 trial of Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) in patients with renal cell cancer. Preliminary data from the Phase 1 trial suggests that the combination of IL-21 and sorafenib is well tolerated, with a toxicity profile similar to known toxicities of each agent alone. This combination therapy has also shown promising anti-tumor activity. Source: www.zymogenetics.com/
THE NHS in the North West failed to spend almost £200m last year yet hospitals in Merseyside are still making cuts and patients are still being denied treatment. Source: Liverpool Daily Post
ZymoGenetics, Inc. today presented positive Phase 1 interim data from a Phase 1/2 trial of Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) in patients with renal cell cancer. Preliminary data from the Phase 1 trial suggests that the combination of IL-21 and sorafenib is well tolerated, with a toxicity profile similar to known toxicities of each agent alone. This combination therapy has also shown promising anti-tumor activity. Source: PRNewswire-FirstCall
Cleveland BioLabs, Inc. (NASDAQ: CBLI) (BOST: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 9th Annual Global Healthcare Conference, on November 5-7, in New York City. Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer and will begin a second Phase II trial in Renal Cell Carcinoma in late 2007. Source: The Global Consulting Group
Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Aida Pharmaceuticals, Inc. today announced an update on its testing of Rh-Apo2L, the next large-scale product to be launched by the Company into the China market. Aida previously announced that it had successfully passed its Phase I tests in July 2006, which consists of tests for safety, dosage and the potential cancer treatments to be tested in Phases II & III. Aida is currently undergoing Phase II testing of Rh-Apo2L testing through China's SFDA, the national drug regulatory agency. Source: Aida Pharmaceuticals
Researchers at the School of Medicine and the Abramson Cancer Center will lead a nationwide trial of anti-cancer drug combinations in patients with advanced kidney cancer, according to a Penn Medicine press release. "This trial takes three proven drugs, and combines then into two drug combinations," Medicine Keith Flaherty said in a statement. "They all seem to attack blood vessel formation in somewhat unique ways, so we think we could get a more profound effect by combining them." The three drugs, bevacizumab, sorafenib and temsirolimus, have been shown to slow the progression of metastic cancer when used alone by starving the cancer cells of the oxygenated blood required for growth. Flaherty and other researchers will determine which combination is most effective by seeing how long it takes patients' tumors to start growing again while on treatment. The longer the period of progression-free treatment, the more effective the drug combination is. The results of the trial may influence how other cancers, including breast, lung and colon cancers, are treated. University researchers will collaborate with the Eastern Cooperative Oncology Group, a network of researchers, physicians and health care professionals, for the trial. Source: The Daily Pennsylvanian
Exelixis, Inc. today announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Francisco. In addition, phase 1 data for XL184, which inhibits MET, VEGFR2 and RET, will also be presented. In total, 13 abstracts for eight compounds have been accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518. Source: Exelixis, Inc and pharmalive.com
Postmenopausal women who are overweight or obese appear to have a greater risk of developing, renal cell carcinoma, a common form of kidney cancer, and study findings suggest that a larger waist girth and a history of weight loss and regain further increase this risk. Source: American Journal of Epidemiology "Our study suggests that the risk of renal cell carcinoma can be lowered if overweight individuals lose excess central body fat and then maintain stable weight at a more desirable level," Dr. Juhua Luo, of Karolinska Institutet, Stockholm, Sweden told Reuters Health.
|Powered by NeonCRM|